Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran

BACKGROUND: Idarucizumab is a monoclonal antibody fragment that reverses dabigatran anticoagulation. Pharmacokinetics (PK) of idarucizumab have been described in healthy, elderly, or renally impaired (RI) volunteers, but PK data in patients are lacking. OBJECTIVES: This analysis describes the PK of...

Descripción completa

Detalles Bibliográficos
Autores principales: Glund, Stephan, Coble, Kelly, Gansser, Dietmar, Stangier, Joachim, Hoermann, Karin, Pollack, Charles V., Reilly, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
CLINICAL HAEMOSTASIS AND THROMBOSIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852568/
https://www.ncbi.nlm.nih.gov/pubmed/31050868
http://dx.doi.org/10.1111/jth.14476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852568/
https://www.ncbi.nlm.nih.gov/pubmed/31050868
http://dx.doi.org/10.1111/jth.14476

Ejemplares similares